Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DermTech, Inc. - Common Stock (NQ: DMTK )

0.0940 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DermTech, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
DermTech Presents Precision Approaches to Personalized Dermatology at 2021 Dermatology Drug Development Summit
From DermTech, Inc.
Via Business Wire
Better Buy: 10x Genomics vs. DermTech
Both companies offer disruptive new solutions in their niches of the healthcare space. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Valneva (NASDAQ:VALN) shares increased by 24.51% to $50.34 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6... 
Via Benzinga
Recap: DermTech Q2 Earnings
Shares of DermTech (NASDAQ:DMTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 1.72% over the past year to ($0... 
Via Benzinga
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time to start another busy day of trading with a dive into the biggest pre-market stock movers for Wednesday. 
Via InvestorPlace
30 Stocks Moving in Wednesday's Pre-Market Session
Gainers RenovoRx, Inc. (NASDAQ: RNXT) rose 113% to $11.50 in pre-market trading. The company, on Tuesday evening, made a presentation on intra-arterial chemotherapy as a... 
Via Benzinga
DermTech Reports Third Quarter 2021 Financial Results
From DermTech, Inc.
Via Business Wire
DermTech's Return On Capital Employed Overview
DermTech (NASDAQ:DMTK) brought in sales totaling $3.12 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.03%, resulting in a loss of $17... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion. As per the... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
DermTech and DermatologistOnCall Enter Agreement to Improve Access to the DermTech Melanoma Test with Noninvasive, At-Home Sample Collection
From DermTech, Inc.
Via Business Wire
DermTech Management to Participate in Upcoming Investor Conferences
From DermTech, Inc.
Via Business Wire
DermTech to Announce Third Quarter Financial Results on November 9, 2021
From DermTech, Inc.
Via Business Wire
3 Things About DermTech That Smart Investors Know
These three facts can help you determine whether you want in on this fast-growing company. 
Via The Motley Fool
DermTech Presents in Expert Panel at Inaugural Alliance for Innovation in Integrated Healthcare Summit
From DermTech
Via Business Wire
DermTech Announces New Appointment of L’Oréal USA Leader Nathalie Gerschtein Keraudy to its Board of Directors
From DermTech, Inc.
Via Business Wire
DermTech Sponsors San Diego Open; Partners with Tennis Pro Brandon Nakashima to Raise Awareness for Sun Safety
From DermTech, Inc.
Via Business Wire
How DermTech Could Change Skin Cancer Testing -- Or Fizzle Out
DermTech's innovative skin treatment is making it easier and cheaper to test for skin cancer, causing the business to grow. Fast. 
Via The Motley Fool
DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine
From DermTech, Inc.
Via Business Wire
Should Investors Be Concerned About DermTech?
Be concerned? No. Be patient? Yes. 
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
Their growth prospects are massive. 
Via The Motley Fool
DermTech Management to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
From DermTech, Inc.
Via Business Wire
DermTech to Present at Florida Association of Health Plans 2021 Annual Conference
From DermTech, Inc.
Via Business Wire
DermTech Management to Participate at the Lake Street 2021 BIG5 Conference
From DermTech, Inc.
Via Business Wire
Looking into DermTech's Return on Capital Employed
Pulled from Benzinga Pro data DermTech (NASDAQ:DMTK) reported Q2 sales of $3.12 million. Earnings fell to a loss of $17.31 million, resulting in a 29.03% decrease from last... 
Via Benzinga
Why Shares of DermTech Dropped 19% in July
The company's noninvasive skin genomics platform has great potential, but its losses have made investors wary. 
Via The Motley Fool
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Scopus BioPharma (NASDAQ:SCPS) s... 
Via Benzinga
DermTech Reports Second Quarter 2021 Financial Results
From DermTech, Inc.
Via Business Wire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.